
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EDARAVONE INJECTION safely and effectively. See full prescribing information for EDARAVONE INJECTION.
EDARAVONE injection, for intravenous use
Initial U.S. Approval: 2017
• Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). (1)
DOSAGE AND ADMINISTRATION
• Edaravone injection: The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes (2.1)
 Initial treatment cycle: daily dosing for 14 days followed by a 14- day drug-free period (2.1) Subsequent treatment cycles: daily dosing for 10 days out of 14- day periods, followed by 14-day drug-free periods (2.1)
DOSAGE FORMS AND STRENGTHS
 Injection: 30 mg/100 mL in a single-dose USP Type 1 Glass Vial (3)
 Injection: 60 mg/100 mL in a single-dose USP Type 1 Glass Vial (3)
CONTRAINDICATIONS
Patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in edaravone injection (4)
WARNINGS AND PRECAUTIONS
 Hypersensitivity Reactions: Advise patients to seek immediate medical care (5.1)
 Sulfite Allergic Reactions: Edaravone injection contains sodium bisulfite, which may cause allergic type reactions, including anaphylactic symptoms and asthmatic episodes in susceptible people (5.2)
ADVERSE REACTIONS
Most common adverse reactions (at least 10% of patients treated with edaravone injection and greater than placebo) are contusion, gait disturbance, and headache (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact XGen Pharmaceuticals DJB, Inc. at 1- 866-390-4411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy: Based on animal data, may cause fetal harm. (8.1) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
See 17 for PATIENT COUNSELING INFORMATION. Revised: 9/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Dosage Information
- 2.2 Preparation and Administration Information for Edaravone Injection
- 2.4 Switching from Edaravone Injection to RADICAVA ORS®
- **3 DOSAGE FORMS AND STRENGTHS**

4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity Reactions 5.2 Sulfite Allergic Reactions **6 ADVERSE REACTIONS** 6.1 Clinical Trials Experience 6.2 Postmarketing Experience **8 USE IN SPECIFIC POPULATIONS** 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use **11 DESCRIPTION** 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics **13 NONCLINICAL TOXICOLOGY** 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility **14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING** 16.1 How Supplied 16.2 Storage and Handling **17 PATIENT COUNSELING INFORMATION** PATIENT INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Information

The recommended dosage of edaravone injection is as follows:

• an intravenous infusion of 60 mg administered over a 60-minute period.

Administer edaravone injection according to the following schedule:

- An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period
- Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods

2.2 Preparation and Administration Information for Edaravone Injection

Edaravone injection is for intravenous infusion only.

Preparation

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Vial may be inverted for use with a medical infusion set. Prepare the dose for administration by inserting a vented intravenous set through the septum of the 100 mL vial. Examine the container contents before dose preparation or administering. DO NOT USE if particulate matter or discoloration is observed, or if the flip off seal is not intact.

Administration

30 mg/100 mL single-dose vials:Administer each 60 mg dose of edaravone injection as two consecutive 30 mg intravenous infusion single-dose vials over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]).

60 mg/100 mL single-dose vials:Administer a 60 mg dose of edaravone injection as an intravenous infusion single-dose vial over a total of 60 minutes (infusion rate approximately 1 mg per minute [1.67 mL per minute]).

Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction [see WARNINGS AND PRECAUTIONS (5.1, 5.2)].

Other medications should not be injected into the single-dose vial or mixed with edaravone injection.

2.4 Switching from Edaravone Injection to RADICAVA ORS®

Patients treated with 60 mg of edaravone intravenous infusion may be switched to 105 mg (5 mL) RADICAVA ORS® using the same dosing frequency.

3 DOSAGE FORMS AND STRENGTHS

Edaravone injection is supplied for intravenous infusion in a single-dose USP Type 1 Glass Vial containing **30 mg** or **60 mg**of edaravone in 100 mL of clear, colorless aqueous solution.

4 CONTRAINDICATIONS

Edaravone injection is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product. Hypersensitivity reactions and anaphylactic reactions have occurred [see WARNINGS AND PRECAUTIONS (5.1, 5.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of

anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports with edaravone injection.

Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue edaravone injection, treat per standard of care, and monitor until the condition resolves [see CONTRAINDICATIONS (4)].

5.2 Sulfite Allergic Reactions

Edaravone injection contains sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity occurs more frequently in asthmatic than non-asthmatic people.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS (5.1)]
- Sulfite Allergic Reactions [see WARNINGS AND PRECAUTIONS (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In randomized, placebo-controlled trials, 184 patients with ALS were administered edaravone injection 60 mg in treatment cycles for 6 months. The population consisted of Japanese patients who had a median age of 60 years (range 29-75) and were 59% male. Most (93%) of these patients were living independently at the time of screening.

Most Common Adverse Reactions Observed During Clinical Studies

Table 2 lists the adverse reactions that occurred in $\geq 2\%$ of patients in the edaravone injection-treated group and that occurred at least 2% more frequently than in the placebo-treated group in randomized placebo-controlled ALS trials. The most common adverse reactions that occurred in $\geq 10\%$ of edaravone injection-treated patients were contusion, gait disturbance, and headache.

Table 2: Adverse Reactions from Pooled Placebo-Controlled Trials ^a that Occurred in ≥2% of Edaravone Injection-Treated Patients and ≥2% More Frequently than in Placebo Patients

Adverse Reaction	Edaravone Injection (N=184) %	Placebo (N=184) %
Contusion	15	9
Gait disturbance	13	9

Headache	10	6
Dermatitis	8	5
Eczema	7	4
Respiratory failure, respiratory disorder, hypoxia	6	4
Glycosuria	4	2
Tinea infection	4	2

^aPooled placebo-controlled studies include two additional studies with 231 additional patients, all using the same treatment regimen [*see CLINICAL STUDIES (14)*].

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of edaravone injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: Hypersensitivity reactions and anaphylaxis [see WARNINGS AND PRECAUTIONS (5.1, 5.2)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

<u>Risk Summary</u>

There are no adequate data on the developmental risk associated with the use of edaravone injection in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity (*see ANIMAL DATA*).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk for major birth defects and miscarriage in patients with ALS is unknown.

<u>Data</u>

Animal Data

In rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. In dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. Maternal toxicity was also observed at the highest dose tested. There were no adverse effects on reproductive function in the offspring. A no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg for edaravone injection on a body surface area (mg/m^2) basis.

In rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. The higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (RHD) for edaravone injection on a body surface area (mg/m²) basis.

The effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from GD 17 throughout lactation, were assessed in two studies. In the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. In the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. Reproduction function in offspring was not affected in either study. Maternal toxicity was evident in both studies at all but the lowest dose tested. The no-effect dose for developmental toxicity (3 mg/kg/day) is less than the RHD on a mg/m 2 basis.

8.2 Lactation

<u>Risk Summary</u>

There are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Edaravone and its metabolites are excreted in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for edaravone injection and any potential adverse effects on the breastfed infant from edaravone injection or from the underlying maternal condition.

8.4 Pediatric Use

Safety and effectiveness of edaravone injection in pediatric patients have not been established.


8.5 Geriatric Use

Of the 184 patients with ALS who received edaravone injection in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

11 DESCRIPTION

The active ingredient in edaravone injection is edaravone, which is a member of the substituted 2-pyrazolin-5-one class. The chemical name of edaravone is [3-methyl-1-phenyl-2-pyrazolin-5-one]. The molecular formula is C $_{10}$ H $_{10}$ N $_2$ O and the molecular weight is 174.20.

The chemical structure is:



Edaravone is a white crystalline powder with a melting point of 129.7°C. It is freely soluble in acetic acid, methanol, or ethanol and slightly soluble in water or diethyl ether.

Edaravone injection is a clear, colorless liquid provided as a sterile solution.

30 mg/100 mL single-dose vials:Edaravone injection is supplied for intravenous infusion in a USP Type 1 Glass Vial containing 30 mg edaravone in 100 mL isotonic, sterile, aqueous solution. Individual vial will be placed in a carton (secondary packaging). Each single-dose vial contains the following inactive ingredients: L-cysteine hydrochloride hydrate (10 mg), sodium bisulfite (20 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4.

60 mg/100 mL single-dose vials:Edaravone injection is supplied for intravenous infusion in a USP Type 1 Glass Vial containing 60 mg edaravone in 100 mL isotonic, sterile, aqueous solution. Individual vial will be placed in a carton (secondary packaging). Each single-dose vial contains the following inactive ingredients: L-cysteine hydrochloride hydrate (20 mg), sodium bisulfite (40 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism by which edaravone injection exerts its therapeutic effect in patients with ALS is unknown.

12.2 Pharmacodynamics

Cardiac Electrophysiology

At exposures at least 5 times higher than that of the recommended doses of edaravone injection, edaravone does not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

Edaravone injection is administered by IV infusion. The maximum plasma concentration (C $_{max}$) of edaravone was reached by the end of infusion. There was a trend of more than dose-proportional increase in area under the concentration-time curve (AUC) and C $_{max}$ of edaravone. With multiple-dose administration, edaravone does not accumulate in plasma.

<u>Distribution</u>

Edaravone is bound to human serum proteins (92%), mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L. Edaravone has a mean volume of distribution after intravenous administration of 63.1 L.

Elimination

The mean terminal elimination half-life of edaravone is approximately 4.5 to 9 hours. The half-lives of its metabolites are 3 to 6 hours. Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h.

Metabolism

Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases.

Excretion

In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and < 1% of the dose was recovered in the urine as the unchanged drug. *In vitro* studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine.

Specific Populations

Geriatric Patients

No age effect on edaravone pharmacokinetics has been found [see USE IN SPECIFIC POPULATIONS (8.5)].

Patients with Renal Impairment

Following single IV infusion of 30 mg edaravone (half the recommended dosage of edaravone injection) over 60 minutes, mean C _{max} and AUC _{0-∞} of unchanged edaravone were 1.15- and 1.20-fold greater in the subjects with mild renal impairment (eGFR 60-89 mL/min/1.73m²), and were 1.25- and 1.29-fold greater in the subjects with moderate renal impairment (eGFR 30-59 mL/min/1.73m²) when compared to subjects with normal renal function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with mild to moderate renal impairment. The effects of severe renal impairment on the pharmacokinetics of edaravone have not been studied.

Patients with Hepatic Impairment

Following single IV infusion of 30 mg edaravone (half of the recommended dose of edaravone injection) over 60 minutes, mean C $_{max}$ and AUC $_{0-\infty}$ of unchanged edaravone were 1.20- and 1.07-fold greater in the subjects with mild hepatic impairment (Child-Pugh score 5 or 6), were 1.24- and 1.14-fold greater in the subjects with moderate hepatic impairment (Child-Pugh score 7 to 9), and were 1.20- and 1.19-fold greater in the subjects with severe hepatic impairment (Child-Pugh score 10 to 14) when

compared to subjects with normal hepatic function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with hepatic impairment.

Male and Female Patients

No gender effect on edaravone pharmacokinetics has been found.

Racial or Ethnic Groups

There were no significant racial differences in C $_{\rm max}$ and AUC of edaravone between Japanese and Caucasian subjects.

Drug Interaction Studies

The pharmacokinetics of edaravone is not expected to be significantly affected by inhibitors of cytochrome P450 (CYP) enzymes, UGTs or major transporters.

In vitro studies demonstrated that, at the recommended dosage, edaravone and its metabolites are not expected to significantly inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A), conjugating enzymes UGT1A1 and UGT2B7, or other transporters (P-gp, OATP1B1, OATP1B3, OAT1, OCT2, MATE1, and MATE2-K) in humans. Edaravone and its metabolites are not expected to induce CYP1A2, or CYP2B6, at the recommended dosage of edaravone.

In vitro data indicated that edaravone was not a substrate of OATP1B1 or OATP1B3.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u>

Carcinogenicity studies of edaravone using the intravenous route have not been conducted.

<u>Mutagenesis</u>

Edaravone was negative in *in vitro* (bacterial reverse mutation and Chinese hamster lung chromosomal aberration) and *in vivo* (mouse micronucleus) assays.

Impairment of Fertility

Intravenous administration of edaravone (0, 3, 20, or 200 mg/kg) prior to and throughout mating in male and female rats and continuing in females to gestation day 7 had no effect on fertility; however, disruption of the estrus cycle and mating behavior was observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to approximately 3 times the RHD for edaravone injection (60 mg) on a body surface area (mg/m²) basis.

14 CLINICAL STUDIES

The efficacy of edaravone injection for the treatment of ALS was established in a 6month, randomized, placebo-controlled, double-blind study conducted in Japanese patients with ALS who were living independently and met the following criteria at screening:

- Functionality retained most activities of daily living (defined as scores of 2 points or better on each individual item of the ALS Functional Rating Scale - Revised [ALSFRS-R; described below])
- Normal respiratory function (defined as percent-predicted forced vital capacity values of [%FVC] ≥80%)
- 3. Definite or Probable ALS based on El Escorial revised criteria
- 4. Disease duration of 2 years or less

The study enrolled 69 patients in the edaravone injection arm and 68 in the placebo arm. Baseline characteristics were similar between these groups, with over 90% of patients in each group being treated with riluzole.

Edaravone injection was administered as an intravenous infusion of 60 mg given over a 60-minute period according to the following schedule:


- An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period (Cycle 1)
- Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (Cycles 2-6).

The primary efficacy endpoint was a comparison of the change between treatment arms in the ALSFRS-R total scores from baseline to Week 24. The ALSFRS-R scale consists of 12 questions that evaluate the fine motor, gross motor, bulbar, and respiratory function of patients with ALS (speech, salivation, swallowing, handwriting, cutting food, dressing/hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency). Each item is scored from 0-4, with higher scores representing greater functional ability. The decline in ALSFRS-R scores from baseline was significantly less in the edaravone injection-treated patients as compared to placebo (see Table 3). The distribution of change in ALSFRS-R scores from baseline to Week 24 by percent of patients is shown in Figure 1.

Table 3: Analysis of Change from Baseline to Week 24 inALSFRS-R Scores

Treatment	Change from Baseline LS Mean ± SE(95% CI)	Treatment Difference (Edaravone Injection - placebo [95% CI])	<i>p</i> - value
Edaravone Injection	-5.01±0.64	2.49 (0.99, 3.98)	0.0013
Placebo	-7.50 ± 0.66		

Figure 1 Distribution of Change from Baseline to Week 24 in ALSFRS-R Scores



16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Edaravone injection is supplied as a 30 mg/100 mL (0.3 mg/mL) clear, colorless, sterile solution for intravenous infusion in single-dose USP Type 1 Glass Vial [see DOSAGE AND ADMINISTRATION (2.2)and HOW SUPPLIED/STORAGE AND HANDLING (16.2)]. These are supplied in cartons as listed below.

- 30 mg/100 mL: NDC 39822-4500-1 single-dose glass vial, 1 vial per carton NDC 39822-4500-2
- 60 mg/100 mL: NDC 39822-4510-1 single-dose glass vial, 1 vial per carton NDC 39822-4510-2

16.2 Storage and Handling

Store edaravone injection at up to 25°C (77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.

17 PATIENT COUNSELING INFORMATION

Advise the patients to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Advise patients to seek immediate medical care if they experience signs or symptoms of a hypersensitivity reaction [see WARNINGS AND PRECAUTIONS (5.1)].

Sulfite Allergic Reactions

Advise patients about potential for sulfite sensitivity. Inform patients that edaravone injection contains sodium bisulfite, which may cause allergic type reactions including

anaphylactic symptoms and life-threatening or less severe asthmatic episodes, and to seek immediate medical care if they experience these signs or symptoms [see WARNINGS AND PRECAUTIONS (5.2)].

Pregnancy and Breastfeeding

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during edaravone injection therapy [see USE IN SPECIFIC POPULATIONS (8.1)].

Advise patients to notify their healthcare provider if they intend to breastfeed or are breastfeeding an infant [see USE IN SPECIFIC POPULATIONS (8.2)].

Manufactured in India

Rx only

Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814

Revised: 09/2024 EDAR-PI-01

RADICAVA ORS® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.

TN00006382

PATIENT INFORMATION

EDARAVONE INJECTION

(e-dar-a-vone)

For Intravenous Infusion

What is edaravone injection?

Edaravone injection is a prescription medicine used to treat people with amyotrophic lateral sclerosis (ALS).

It is not known if edaravone injection is safe and effective in children.

Do not receive edaravone injection if you are allergic to edaravone or any of the ingredients in edaravone injection. See the end of this leaflet for a complete list of ingredients in edaravone injection.

Before you receive edaravone injection, tell your healthcare provider about all of your medical conditions, including if you:

- have asthma.
- are allergic to other medicines.
- are pregnant or plan to become pregnant. It is not known if edaravone injection will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if edaravone passes into your breastmilk. You and your healthcare provider should decide if you will receive edaravone injection or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and

over-the-counter medicines, vitamins, and herbal supplements.

How will I receive edaravone injection?

- You will be prescribed edaravone injection by a healthcare provider and told how often you will receive edaravone injection.
- Edaravone injection will be given by intravenous (IV) infusion into your vein.
- It takes about 1 hour to receive the full dose of edaravone injection.
- Your healthcare provider will monitor you closely during your treatment with edaravone injection.

What are the possible side effects of edaravone injection?

Edaravone injection may cause serious side effects including:

- 1. Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving edaravone injection and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:
- hives
- swelling of the lips, tongue, face
- breathing problems
- dizziness
- itching
- wheezing
- fainting
- 1. Sulfite allergic reactions. Edaravone injection contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:
- hives
- swelling of the lips, tongue, face
- trouble breathing or swallowing
- dizziness
- itching
- asthma attack (in people with asthma)
- wheezing
- fainting

Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all serious side effects and allergic reactions.

The most common side effects of edaravone injection include bruising (contusion), problems walking (gait disturbance), and headache.

These are not all the possible side effects of edaravone injection. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side

effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch or XGen Pharmaceuticals DJB, Inc. at 1-866-390-4411.

What are the ingredients in edaravone injection?


Active ingredient: edaravone

Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride (tonicity agent), phosphoric acid (pH adjuster), and sodium hydroxide (pH adjuster).

Manufactured in India for: XGen Pharmaceuticals DJB, Inc., Big Flats, NY 14814

This Patient Information has been approved by the U.S. Food and Drug Administration

Issued: 09/2024 EDAR-PIL-01





EDARAVONE

Route of Administration INTRAVENOUS Active Ingredient/Active Molety Ingredient Name Basis of Strength Strength EDARAVONE (UNII: S798V6YJRP) (EDARAVONE - UNII:S798V6YJRP) EDARAVONE 30 mg in 10 Inactive Ingredients Ingredient Name Basis of Strength 30 mg in 10 Inactive Ingredients Ingredient Name 20 mg in 100 mL 30 mg in 100 mL SODIUM BISULFITE (UNII: TZX546926i) 20 mg in 100 mL 30 mg in 100 mL 300 mg in 100 mL SODIUM CHLORIDE (UNII: ZT334N0X4W) 10 mg in 100 mL 300 mg in 100 mL 300 mg in 100 mL SODIUM CHLORIDE (UNII: ST3040C320) PhoSPHORIC ACID (UNII: E4GAB884NN) 400 mL 30 mg in 100 mL PHOSPHORIC ACID (UNII: E4GAB884NN) WATER (UNII: 0590F0ROR) 12/02/2024 400 mL Packaging # tem Code Package Description 12/02/2024 100 mL in 10 ML MDC:39822- 10 in 1.1 VIAL, SINGLE-DOSE; Type 0: Not a 12/02/2024 100 mL in 20 mL Marketing Category Application Number or Monograph Category Marketing Date Marketing Date ANDA ANDA217565 12/02/2024 100 mL 10 mL	edaravone injec	tion, solution					
Route of Administration INTRAVENOUS INTRAVENOUS Active Ingredient/Active Molety Ingredient Name Basis of Strength Strength EDARAVONE (UNII: S798V6YJRP) (EDARAVONE - UNII:S798V6YJRP) EDARAVONE Strength Ingredient Name Strength Ingredient Name Strength Strength Strength Strength Strength Marketing St	Product Info	rmation					
Route of Administration INTRAVENOUS Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength EDARAVONE (UNII: S798V6Y)RP) (EDARAVONE - UNII:S798V6Y)RP) EDARAVONE 30 mg in 1 Ingredient Name Strength SODIUM Enclose (UNII: T2X5469261) 20 mg in 100 mL 20 mg in 100 mL SODIUM BISULFITE (UNII: T2X5469261) 20 mg in 100 mL 300 mg in 100 mL SODIUM HURDRDE (UNII: T2X5469261) 20 mg in 100 mL 300 mg in 100 mL SODIUM CHLORIDE (UNII: T2X5469261) 20 mg in 100 mL 300 mg in 100 mL SODIUM CHLORIDE (UNII: T2X5469261) 20 mg in 100 mL 300 mg in 100 mL SODIUM CHLORIDE (UNII: ST0AQC321) PHOSPHORIC ACID (UNII: E4GA8884NN) 00 mg in 100 mL SODIUM HYDROXIDE (UNII: S5X0AQC321) PHOSPHORIC ACID (UNII: E4GA8884NN) 12/02/2024 Marketing Date 1 NDC:39822- 1 in 1 CARTON 12/02/2024 1 Marketing Combination Product Marketing Information Marketing Start Omination Product Marketing Start Omination Product Marketing Start Omination Product Marketing Category AnDA217565 12/02/2024	Product Type		HUMAN PRESCRIPTION DRUG	Ite	m Code (So	urce)	NDC:39822-4500
Active Ingredient/Active Molety Ingredient Name EDARAVONE (UNII: 5798V6Y)RP) (EDARAVONE - UNII:5798V6Y)RP) EDARAVONE (UNII: 5798V6Y)RP) (EDARAVONE - UNII:5798V6Y)RP) Inactive Ingredients Ingredient Name SoDium BISULFITE (UNII: T2 X546926) 20 mg in 100 mL 20 mg in 100 mL		nistration	INTRAVENOUS				
Ingredient Name Basis of Strength Strength EDARAVONE (UNII: S798V6YJRP) (EDARAVONE - UNII:S798V6YJRP) EDARAVONE 30 mg in 1 Inactive Ingredients Ingredient Name Strength SODIUM BISULFITE (UNII: TZ X546926I) 20 mg in 100 mL CYSTEINE HYDROCHLORIDE (UNII: TZ 7934N0X4W) 10 mg in 100 mL SODIUM CHLORIDE (UNII: 451W47IQ8X) 30 mg in 100 mL SODIUM CHLORIDE (UNII: 55X04QC32I) 10 mg in 100 mL PHOSPHORIC ACID (UNII: E4GA8884NN) 30 mg in 100 mL WATER (UNII: 059QF0K00R) 10 mg in 100 mL Packaging # # Item Code Package Description Marketing Start Date Marketing Date 1 NDC: 39822- 1 NDC: 39822-	Noute of Admin	listration					
EDARAVONE (UNII: S798V6YJRP) (EDARAVONE - UNII: S798V6YJRP) EDARAVONE 30 mg in 1 Inactive Ingredients Ingredient Name Ingredie	Active Ingree	lient/Active	Moiety				
Ingredients Ingredient Name Strength SoDiUM BISULFITE (UNII: TZX546926I) 20 mg in 100 mL CYTEINE HYDROCHLORIDE (UNII: T27934N0X4W) 10 mg in 100 mL SoDIUM CHLORIDE (UNII: S5X04QC32I) PHOSPHORIC ACID (UNII: E4GA8884NN) WATER (UNII: 0590F0KOOR) Packaging # Item Code Package Description Marketing Start Date Marketing Date 1 NDC:39822- 4500-2 1 in 1 CARTON 12/02/2024 1 1 NDC:39822- 4500-1 1 in 1 CARTON 12/02/2024 1 Marketing Information Marketing Information Marketing Start Marketing Date AnDA ANDA217565 12/02/2024 EDARAVONE edaravone injection, solution		Ingredie	ent Name		Basis of St	rength	Strength
Ingredient Name Strength Solum BisulFite (UNII: TZX5469261) 20 mg in 100 mL Cysteine Hydrochloride (UNII: TZ7934N0X4W) 10 mg in 100 mL Solum CHLORIDE (UNII: ST034N02X30) Solum CHLORIDE (UNII: S5X04QC320) PHOSPHORIC ACID (UNII: E4GA8884NN) Water (UNII: 059QF0K00R) Marketing Start Date Marketing Start On mL in 1 CARTON Application Number or Monograph Citation Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Date Application Number or Monograph Citation Marketing Linformation EDARAVONE	E DARAVONE (UNI	I: S798V6YJRP) (E	:DARAVONE - UNII:S798V6YJRP)	E	EDARAVONE		30 mg in 100 mL
SODIUM BISULFITE (UNII: TZX546926i) 20 mg in 100 mL CYSTEINE HYDROCHLORIDE (UNII: 451W47IQ8X) 10 mg in 100 mL SODIUM CHLORIDE (UNII: 55X04QC32I)	Inactive Ingr	edients					
CYSTEINE HYDROCHLORIDE (UNII: ZT934N0X4W) 10 mg in 100 mL SODIUM CHLORIDE (UNII: 451W47IQ8X) 10 mg in 100 mL SODIUM HYDROXIDE (UNII: 55X04QC32)) 10 mg in 100 mL PHOSPHORIC ACID (UNII: E4GA8884NN) 10 mg in 100 mL WATER (UNII: 0590F0KOR) 10 mg in 100 mL Prockaging Marketing Start A500-2 Marketing Start A500-2 Marketing Description Marketing Start A500-2 Marketing Date 1 NDC:39822- 4500-1 10 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product 12/02/2024 1 Marketing Date Marketing Category Application Number or Monograph Citation Marketing Date Marketing Date ANDA ANDA217565 12/02/2024 1 12/02/2024		In	gredient Name				Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X) SODIUM HYDROXIDE (UNII: 55X04QC32I) PHOSPHORIC ACID (UNII: E4GA8884NN) WATER (UNII: 059QF0K00R) PACKAGGING PACKAGG PACKAGG Description Marketing Start Date Marketing Start Combination Product Marketing Information Marketing Citation Number or Monograph Marketing Start Date ANDA ANDA217565 12/02/2024 Marketing Date EDARAVONE edaravone injection, solution	SODIUM BISULFI	TE (UNII: TZ X546	59Z 6I)			20 mg in	i 100 mL
SODIUM HYDROXIDE (UNII: 55X04QC32I) PHOSPHORIC ACID (UNII: E4GA8884NN) WATER (UNII: 059QF0K00R) Packaging # Item Code Package Description Marketing Start Date 1 NDC: 39822- 1 NDC:						10 mg in	i 100 mL
PHOSPHORIC ACID (UNII: E4GA88884NN) WATER (UNII: 059QF0KOOR) Packaging Item Code Package Description Marketing Start Marketing Date 1 NDC:39822- 4500-2 1 in 1 CARTON 1 NDC:39822- 2600-1 1 NDC:39822- 2600-1 1 NDC:39822- 2600-1 NDC:39822- 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a 2600-1 Marketing Start Combination Product Marketing Start Date Marketing Start Da	SODIUM CHLORI	DE (UNII: 451W47	/IQ8X)				
WATER (UNII: 059QF0K00R) Marketing Start Marketing Start # Item Code Package Description Marketing Start Marketing Date 1 NDC:39822- 4500-2 1 in 1 CARTON 12/02/2024 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product Marketing Start Marketing Date Marketing Information Marketing Category Category Category Application Number or Monograph Citation Marketing Start Marketing Date ANDA ANDA217565 12/02/2024 Marketing Date EUARAVONE							
Marketing Start S			84NN)				
# Item Code Package Description Marketing Start Date Marketing Marketing 12/02/2024 1 NDC: 39822- 4500-1 1 in 1 CARTON 12/02/2024 12/02/2024 NDC: 39822- 4500-1 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product Marketing Start Marketing Date Marketing Category Application Number or Monograph Citation Marketing Start Marketing Date ANDA ANDA217565 12/02/2024 12/02/2024	WATER (UNII: 059	QF0KO0R)					
MDC: 39822- 4500-2 1 in 1 CARTON 12/02/2024 NDC: 39822- 4500-1 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product 12/02/2024 Marketing Category Category ANDA Application Number or Monograph Citation Marketing Start Date Marketing Date ANDA ANDA217565 12/02/2024 12/02/2024		Р	ackage Description				Marketing End
4500-2 NDC:39822- 4500-1 100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product Image: Combination Product Marketing Category ANDA Application Number or Monograph Citation Marketing Start Date Marketing Category Date ANDA ANDA217565 12/02/2024 Image: Combination Product	NDC:39822-					9	Date
Marketing Information Application Number or Monograph Citation Marketing Start Date Marketing Start Date ANDA ANDA217565 12/02/2024 12/02/2024 EDARAVONE edaravone injection, solution Product Information Information	NDC:39822-						
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Other Date ANDA ANDA217565 12/02/2024 12/02/2024 EDARAVONE edaravone injection, solution Froduct Information Information	4500 1	Combination 110	Juct				
Category Citation Date Date ANDA ANDA217565 12/02/2024 EDARAVONE edaravone injection, solution Product Information	Marketing	Informat	ion				
EDARAVONE edaravone injection, solution Product Information		Applica				Start	Marketing End Date
edaravone injection, solution Product Information			5	12	2/02/2024		
edaravone injection, solution Product Information	ANDA	ANDAZITJU					
Product Information	ANDA	ANDAZ1750					
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:39822-	EDARAVON	JE					
	EDARAVON edaravone injec	IE tion, solution					
Route of Administration INTRAVENOUS	EDARAVON edaravone injec Product Info	IE tion, solution	HUMAN PRESCRIPTION DRUG	Ite	m Code (So	urce)	NDC:39822-4510

Active Ingredient/Active Moiety

		Ingredient Name	Basis of St	renath	Strength
FDAR/		I: S798V6YJRP) (EDARAVONE - UNII:S798V6YJRP)	EDARAVONE	lengen	60 mg in 100 mL
			EBRUCCILE		
Inac	tive Ingr	edients			
		Ingredient Name			Strength
SODIU	JM BISULFI	TE (UNII: TZX5469Z6I)		40 mg in	100 mL
сүзте	EINE HYDRO	OCHLORIDE (UNII: ZT934N0X4W)		20 mg in	100 mL
SODIU	JM CHLORI	DE (UNII: 451W47IQ8X)			
SODIU	JM HYDRO)	KIDE (UNII: 55X04QC32I)			
PHOS	PHORIC AC	ID (UNII: E4GA8884NN)			
WATE	R (UNII: 059	QF0KO0R)			
Pack	caging				
# Ite	em Code	Package Description	Marketing Date		Marketing End Date
1 NDC 451	C:39822- .0-2	1 in 1 CARTON	12/02/2024		
1 NDC 451	C:39822- .0-1	100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product			
Mar	keting	Information			
м	larketing Category	Application Number or Monograph Citation	Marketing S Date	Start	Marketing End Date
	accigory				
	utegory	ANDA217565	12/02/2024		

Labeler - XGen Pharmaceuticals DJB, Inc. (117380305)

Registrant - XGen Pharmaceuticals DJB, Inc. (117380305)

Revised: 12/2024

XGen Pharmaceuticals DJB, Inc.